X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (120) 120
index medicus (99) 99
humans (86) 86
female (67) 67
male (66) 66
middle aged (66) 66
aged (64) 64
lung neoplasms - drug therapy (50) 50
adult (46) 46
aged, 80 and over (37) 37
carcinoma, non-small-cell lung - drug therapy (36) 36
cancer (35) 35
article (31) 31
chemotherapy (29) 29
lung neoplasms - pathology (29) 29
treatment outcome (29) 29
lung cancer (26) 26
lung cancer, non-small cell (25) 25
antineoplastic agents - therapeutic use (24) 24
tumors (24) 24
immunotherapy (23) 23
neoplasm staging (23) 23
antineoplastic combined chemotherapy protocols - therapeutic use (21) 21
peptides (21) 21
docetaxel (19) 19
carcinoma, non-small-cell lung - pathology (18) 18
care and treatment (18) 18
cell lung-cancer (18) 18
chemistry (18) 18
human necessities (18) 18
hygiene (18) 18
lung neoplasms - genetics (18) 18
medical or veterinary science (18) 18
metallurgy (18) 18
organic chemistry (18) 18
preparations for medical, dental, or toilet purposes (18) 18
respiratory system (18) 18
survival rate (18) 18
gefitinib (17) 17
lung neoplasms - mortality (17) 17
abridged index medicus (16) 16
dose-response relationship, drug (16) 16
neoplasms - drug therapy (16) 16
therapy (16) 16
adenocarcinoma - drug therapy (15) 15
research (15) 15
antibodies, monoclonal - therapeutic use (14) 14
antineoplastic agents - adverse effects (14) 14
carcinoma, non-small-cell lung - mortality (14) 14
patients (14) 14
trial (14) 14
mutation (13) 13
mutations (13) 13
nivolumab (13) 13
safety (13) 13
disease-free survival (12) 12
drug administration schedule (12) 12
erlotinib (12) 12
pharmacology & pharmacy (12) 12
prognosis (12) 12
adenocarcinoma - pathology (11) 11
carcinoma, non-small-cell lung - genetics (11) 11
melanoma (11) 11
survival (11) 11
adenocarcinoma - genetics (10) 10
cohort studies (10) 10
drug therapy (10) 10
infusions, intravenous (10) 10
ipilimumab (10) 10
maximum tolerated dose (10) 10
solid tumors (10) 10
survival analysis (10) 10
antibodies, monoclonal - adverse effects (9) 9
apoptosis (9) 9
beer (9) 9
biochemistry (9) 9
cancer therapies (9) 9
cisplatin (9) 9
compositions or test papers therefor (9) 9
condition-responsive control in microbiological orenzymological processes (9) 9
disease progression (9) 9
enzymology (9) 9
expression (9) 9
growth (9) 9
health aspects (9) 9
hematology, oncology and palliative medicine (9) 9
lung neoplasms - metabolism (9) 9
measuring or testing processes involving enzymes, nucleicacids or microorganisms (9) 9
microbiology (9) 9
mutation or genetic engineering (9) 9
non-small cell lung cancer (9) 9
processes of preparing such compositions (9) 9
quinazolines - therapeutic use (9) 9
receptor, epidermal growth factor - genetics (9) 9
specific therapeutic activity of chemical compounds ormedicinal preparations (9) 9
spirits (9) 9
vinegar (9) 9
wine (9) 9
antineoplastic agents - administration & dosage (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Oncologist, ISSN 1083-7159, 06/2019, Volume 24, Issue 6, pp. 730 - 734
Immune‐related adverse events are challenging to treat, with one of the most serious consequences being pneumonitis. This article reports an illustrative case... 
IMMUNE CHECKPOINT INHIBITORS | CANCER-PATIENTS | MANAGEMENT | INHIBITOR-RELATED PNEUMONITIS | DEATH 1 | ONCOLOGY | LIGAND | ANTI-PD-1 | NIVOLUMAB | ADVERSE EVENTS | IPILIMUMAB
Journal Article
BMC cancer, ISSN 1471-2407, 04/2018, Volume 18, Issue 1, pp. 413 - 413
It has been highlighted that in the original manuscript [1] Table S3 'An example of the predictive computational modeling process. Specific details on an... 
Lung cancer, Non-small cell | Immunotherapy
Journal Article
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 2019, Volume 14, Issue 9, pp. 1547 - 1555
Introduction: Rare cases of early-onset pulmonary events (EOPEs) occurring within days of the start of administration of brigatinib have been reported... 
Brigatinib | Pneumonitis | Interstitial lung disease | Pulmonary event | CELL LUNG-CANCER | ONCOLOGY | RESPIRATORY SYSTEM
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 06/2019
INTRODUCTIONTwo clinical studies (Study 1108 and ATLANTIC) were analyzed to evaluate the prognostic value of baseline liver metastases (LMs) in... 
Journal Article
ISSN 2045-2322, 2016
Medical imaging plays a fundamental role in oncology and drug development, by providing a non-invasive method to visualize tumor phenotype. Radiomics can... 
Phenotype | Cancer--Imaging | Medical radiology | Tumors
Journal Article
Cancer, ISSN 0008-543X, 05/2005, Volume 103, Issue 10, pp. 2128 - 2131
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. LB-072 - LB-072
Background: Nivo, a fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, is approved in the United States and European Union for... 
Journal Article
Journal Article
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 05/2019
We evaluated the impact of patient characteristics, sample types, and prior non-immunotherapy treatment on tumor cell (TC) programmed cell death ligand-1... 
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 299 - 308
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 257 - 265
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 21, pp. 2018 - 2028
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.